Abstract Library

#4658 The nutritional status worsens over 5 years in patients with gastroenteropancreatic neuroendocrine tumours on treatment with somatostatin analogues

Introduction: Malnutrition is common in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with monthly somatostatin analogues (SSAs). Ideally all malnourished patients are offered nutritional support. However, clinical guidelines and data on the development and progression of malnutrition is lacking.

Conference:

Presenting Author: Clement D

Authors: Soran V, Srirajaskanthan R, Cananea E, Martin W, Minott S,

Keywords: gastroenteropancreatic neuroendocrine tumour, malnutrition, somatostatin analogue,

#4643 Characterisation of patients with progressive digestive NET during PRRT (LUTA-CHEC): A multicentre study from the Groupe des Tumeurs Endocrines

Introduction: PRRT with 177Lu-DOTATATE is a major treatment for metastatic digestive NETs. Most patients have prolonged progression-free survival, but around 20% experience early progression.

Conference:

Presenting Author: Haissaguerre M

Authors: Haissaguerre M, Hadoux J, Tlili G, Deshayes E, Lacombe M,

Keywords: GEP-NET, PRRT, early tumour progression,

#4596 Gender and metastatic burden as preoperative predictors of disease progression in patients undergoing surgery for pancreatic neuroendocrine tumours with liver metastases

Introduction: Pancreatic neuroendocrine tumour liver metastases (PanNET LM) are traditionally classified into three types based on their distribution. Surgery is generally considered for patients with type I/II LM, while those with type III LM are typically regarded as unresectable. However, type III PanNET LM encompass a wide range of clinical scenarios, some of which may allow surgical resection in selected cases.

Conference:

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Battistella A, Muffatti F, Tamburrino D,

Keywords: Pan NET, neuroendocrine, liver metastasis, surgery, gender, progression,

#4584 Hepatic cytoreduction in advanced lung neuroendocrine neoplasms: A single institutional case series

Introduction: Role of hepatic cytoreductive surgery in well-differentiated gastroenteropancreatic neuroendocrine neoplasms (NENs) with liver metastases is well-described, however, its role in advanced lung NENs with liver metastases is unknown.

Conference:

Presenting Author: Grewal U

Authors: Grewal U, Patel R, Furqan M, Dillon J, Chandasekharan C,

Keywords: Lung neuroendocrine neoplasm, Hepatic cytoreductive surgery,

#4564 Vasculogenic mimicry in neuroendocrine tumour across different primary sites

Introduction: Anti-angiogenesis treatments targeting VEGFRs, including Surufatinib and Cabozantinib, etc. showed better efficacy for pancreatic neuroendocrine tumours (NET) than NET of other primary sites. Recent clinical trial targeting tumour necrosis factor receptor-associated protein-1, leading to inhibition of vasculogenic mimicry (VM) showed contrary results to current VEGFRs-targeted treatments. However, VM of NET across different primary sites are yet to be understood.

Conference:

Presenting Author: Chen L

Authors: Chen L, Liang Y, Huang D, Ji S, Chen J,

Keywords: neuroendocrine tumour, pancreatic, extra-pancreatic, vasculogenic mimicry,